Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Neoplasms 1 HER2/Neu Negative 1 Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

pembrolizumab 3 Paclitaxel 2 Carboplatin 2 ulixertinib 1 trastuzumab deruxtecan 1 trastuzumab biosimilar HLX02 1 trametinib 1 selinexor 1 sapanisertib 1 relatlimab 1 pertuzumab 1 palbociclib 1 osimertinib 1 omipalisib 1 larotrectinib 1 ipatasertib 1 erdafitinib 1 dostarlimab 1 defactinib 1 dabrafenib 1 copanlisib 1 capivasertib 1 binimetinib 1 adavosertib 1 X-Rays 1 Vaginal Smears 1 VMBP protocol 1 Ultrasound, High-Intensity Focused, Transrectal 1 Trastuzumab 1 Sutures 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Uterine Neoplasms × 16-fluoroestradiol × 90 days × Clear all

NCT05916196 2026-06-05

[18F]FES PET/.CT in Uterine Cancer

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting

Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡